
    
      All patients undergoing SWL are included in study. Exclusion criteria: Patient with
      radio-lucent stone, patients treated with calcium channel blockers, alpha blockers, steroids,
      patients with contraindication to alpha blocker treatment, postural hypotension patents with
      abnormal liver function tests.

      Patient will be recruited to the study prospectively. Following signature on inform consent
      patients will be randomized into 2 groups. One group will be treated with alfuzosin 10mg a
      day and the control group with placebo. Treatment will be initiated following the lithotripsy
      treatment.

      Parameters for investigation includes: demographic and personal data, stone size and location
      (obtained by CT or KUB), pain control medication and visual analogue scale assessment of
      pain, side effects, clinical squeals, stone free out come. Follow up evaluation will be at 1
      week, 1 month, and 3 months post treatment. Success will be defined following CT evaluation
      at 3 months. Treatment ends at stone free achievement or at 3 months.

      Endpoints:Stone free rate, time to stone free, side effect.
    
  